A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients with Relapsed Small Cell Lung Cancer
Description: 

To evaluate the 18-week progression free survival (PFS) rate of relapsed SCLC patients treated with NKTR-102.

Study Number: 

I 225612

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01876446

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.